Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 60

37th Annual J.P. Morgan Healthcare Conference

Posted by fidest press agency su giovedì, 3 gennaio 2019

San Francisco on Wednesday, January 9, 2019 Time: 11:00 a.m. PT Westin St. Francis, Elizabethan D. Merck (NYSE:MRK), Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin therapies, announced today that the company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco Praveen Tipirneni, M.D., president and CEO of Morphic, will provide an overview of the company, its innovative platform for designing integrin oral inhibitors, and anticipated milestones in 2019.Morphic is developing highly differentiated molecules for the treatment of autoimmune diseases, fibrotic diseases, and cancer. In 2018, Morphic announced the completion of a $80 million Series B financing and entered into a research and development collaboration with AbbVie designed to advance a number of Morphic’s oral integrin therapeutics for fibrosis-related indications.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: